Childhood absence epilepsy (CAE), also known as pyknolepsy, is an idiopathic generalized epilepsy which occurs in otherwise normal children. The age of onset is between 4–10 years with peak age between 5–7 years. Children have absence seizures which although brief (~4–20 seconds), they occur frequently, sometimes in the hundreds per day. The absence seizures of CAE involve abrupt and severe impairment of consciousness. Mild automatisms are frequent, but major motor involvement early in the course excludes this diagnosis. The EEG demonstrates characteristic "typical 3Hz spike-wave" discharges. Prognosis is excellent in well-defined cases of CAE with most patients "growing out" of their epilepsy.

Market Analysis and Insights: Global Childhood Absence Epilepsy Treatment Market
The global Childhood Absence Epilepsy Treatment market size is projected to reach US$ 184.9 million by 2027, from US$ 145.1 million in 2020, at a CAGR of 3.1% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Childhood Absence Epilepsy Treatment market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Childhood Absence Epilepsy Treatment market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Childhood Absence Epilepsy Treatment market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Childhood Absence Epilepsy Treatment market.

Global Childhood Absence Epilepsy Treatment Scope and Market Size
Childhood Absence Epilepsy Treatment market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Childhood Absence Epilepsy Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Ethosuximide
Valproate
Lamotrigine
CX-8998
Cannabidiol Oral Solution

Segment by Application
Typical Absence Seizures
Atypical Absence Seizures

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Pfizer
GlaxoSmithKline
Cavion Inc
AbbVie
Teva Pharmaceutical
Insys Therapeutics